COLLECTION AND ANALYSIS Clause Samples

COLLECTION AND ANALYSIS. A. All collection of urine or breath for random testing will be performed at a facility or facilities to be designated by the County or contract vendor. B. The collection site for urine samples will provide a privacy enclosure for urination, a toilet, a suitable, clean, writing surface, and a water source for hand washing which, if practicable, will be outside the privacy enclosure. Any water source within the privacy enclosure will be secured to prevent it s use to adulterate the urine’s sample. C. The employee will be assured of privacy during urination except in circumstances where there is evidence that a prior sample was altered, adulterated or tampered with, in which case a retest will be required and privacy will not be assured. D. The urine specimen must be split and poured into two specimen bottles. This provides the employee with the option of having an analysis of the split sample performed at a separate laboratory if the primary specimen test result is verified positive. ▇. ▇▇▇▇▇ testing will be conducted at a laboratory certified by the United States Department of Health and Human Services. F. All drug testing laboratory results will be reviewed by a qualified Medical Review officer (MRO) to verify and validate test results. A MRO is a licensed physician responsible for receiving laboratory results generated by a drug testing program who has knowledge of substance abuse disorders and has relevant training and qualifications. G. The MOR will review and interpret all confirmed positive tests by reviewing the employee’s medical history, including any medical records and biomedical information provided, affording the employee a reasonable opportunity to discuss the test result, and deciding whether there is a legitimate medical explanation for the result including legally prescribed medication. ▇. The MRO will notify each employee who has a verified positive test that the employee has 72 hours in which to request a test of the split specimen at a separate laboratory. I. Upon completion of the MRO’s review the MRO will report each verified positive test result to the Sheriff. The employee will be removed from his/her duties and will be subject to the consequences outlined in Article VII of this Policy. Removal from duties will be immediate and will not await the result of any requested retest. J. An employee requesting a drug retest will advance the cost of the additional analysis and all costs associated with the transfer of the specimen to anothe...

COLLECTION AND ANALYSIS. After parental informed consent was obtained and the risk-factor questionnaire was completed, two venous blood samples (minimum 1.5mL in a 5mL Vacutainer designed to normally collect 3mL blood) were drawn by a trained phlebotomist from the randomly selected eligible child. If the child was not at the compound, the parent was asked when it would be most convenient for the team to return. If the selected child was not at the compound at any time during the team’s visit to that village, the study team proceeded to the next randomly selected compound. One venous blood sample per child was taken to a central processing laboratory where samples were tested on a LeadCare II (LCII) portable blood lead analyzer by trained members of study team within 24 hours of collection. The other blood sample was sent unopened to the CDC Division of Laboratory Sciences (DLS) for quality assurance/quality control using an Inductively Coupled Plasma Mass Spectrometer. In addition to testing BLL and other blood metal concentrations, CDC tested blood samples for sickle cell status. Blood spots were also collected and dried on ▇▇▇▇▇▇▇ cards. The LCII analyzer, when used according to the CLIA- approved instructions, has a reportable blood lead range of 3.3 µg/dL to 65 µg/dL, reporting only “HI” for blood lead results >65 µg/dL. To identify children with extremely high lead exposures for priority medical treatment, a dilution procedure recommended by the LeadCare II manufacturer was implemented to estimate blood concentrations >65 µg/dL, which has previously been found to provide useful approximations of extremely high BLLs in the field. All supplies used to collect blood were verified lead free by the CDC DLS. All results from the LCII and ▇▇▇▇▇▇▇ card were shared with the MSF physicians accompanying field teams, Zamfara SMoH, and the Nigerian CDC. The Zamfara SMoH was responsible for notifying parents regarding their children’s results. All study team members were trained in counseling parents on their child’s blood lead status. At the time samples were collected, an informational sheet was given to the heads of compounds to inform parents who to contact if they have questions, concerns or problems. Dust and Soil Sampling and Analysis: Environmental sampling was performed to identify villages that engaged in gold ore processing by measuring lead in soil and dust. After administering the compound survey, field teams collected indoor dust samples obtained from piles created by sweepin...

COLLECTION AND ANALYSIS. Top Handler Data collection information and analysis will be provided in the final report (Task 1.5) 8/30/2021

COLLECTION AND ANALYSIS. The goal of this task is to collect operational data from the project, to analyze that data for economic and environmental impacts, and to include the data and analysis in the Final Report. • Develop a data collection plan. • Troubleshoot any issues identified. • Collect at least six months of data, including: o Throughput, usage, and operations data o Normal operating hours, up time, down time, and explanations of variations o Feedstock supply summary o Maximum capacity of the new fuel production system in diesel gallon equivalents (DGE) and ordinary units o Gallons of gasoline and/or diesel fuel displaced (with associated mileage information), along with value converted into DGE o Record of wastes from production processes (waste water, solid waste, criteria emissions, etc.) o Expected air emissions reduction, for example: ▪ Non-methane hydrocarbons ▪ Oxides of nitrogen ▪ Non-methane hydrocarbons plus oxides of nitrogen ▪ Particulate Matter ▪ Formaldehyde o Duty cycle of the current fleet and the expected duty cycle of future vehicle acquisitions o Specific jobs and economic development resulting from this project o Levelized Cost of Fuel and Finished fuel price o Analysis of total facility costs, operation and maintenance costs, marginal abatement costs • Comply with the Petroleum Industry Information Reporting Act (PIIRA) and complete CEC Form M810E and CEC Form M13 on a monthly basis for submission to the California Energy Commission’s PIIRA Data Collection Unit. • Provide a written record of registering with the Low Carbon Fuel Standard and Renewable Fuel Standard programs. • Identify any current and planned use of renewable energy at the facility. • Describe any energy efficiency measures used in the facility that may exceed Title 24 standards in Part 6 of the California Code Regulations. • Provide data on potential job creation, economic development, and increased state revenue as a result of expected future expansion. • Provide a quantified estimate of the project’s carbon intensity values or provide an Air Resources Board approved pathway carbon intensity. • Estimate annual life-cycle greenhouse gas emission reduction. • Compare any project performance and expectations provided in the proposal to Energy Commission with actual project performance and accomplishments. • Collect data, information, and analysis described above and include in the Final Report.

COLLECTION AND ANALYSIS. A. All collection of urine or breath for random testing will be performed at a facility or facilities to be designated by the County or contract vendor. B. The collection site for urine samples will provide a privacy enclosure for urination, a toilet, a suitable, clean, writing surface, and a water source for hand washing which, if practicable, will be outside the privacy enclosure. Any water source within the privacy enclosure will be secured to prevent it’s use to adulterate the urine’s sample. C. The employee will be assured of privacy during urination except in circumstances where there is evidence that a prior sample was altered, adulterated or tampered with, in which case a retest will be required and privacy will not be assured. D. The urine specimen must be split and poured into two specimen bottles. This provides the employee with the option of having an analysis of the split sample performed at a separate laboratory if the primary specimen test result is verified positive. ▇. ▇▇▇▇▇ testing will be conducted at a laboratory certified by the United States Department of Health and Human Services. F. All drug testing laboratory results will be reviewed by a qualified Medical Review officer (MRO) to verify and validate test results. A MRO is a licensed physician responsible for receiving laboratory results generated by a drug testing program that has knowledge of substance abuse disorders and has relevant training and qualifications.